Program Director Kathy S. Albain, MD, FACP Professor of Medicine Division of Hematology/Oncology Loyola University Chicago Stritch School of Medicine Director, Breast Clinical Research Program Director, Thoracic Oncology Program Cardinal Bernardin Cancer Center Maywood, IL
Featured Faculty Clodia Osipo, PhD Associate Professor Department of Pathology Cardinal Bernardin Cancer Center Maywood, IL Ana Maria Gonzalez-Angulo, MD, MSc, FACP Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX Larissa A. Korde, MD, MPH Assistant Professor Department of Medicine Division of Oncology University of Washington Seattle, WA Ian Krop, MD, PhD Assistant Professor, Department of Medicine, Harvard Medical School Instructor in Medicine, Adult Oncology, Dana-Farber Cancer Institute Boston, MA Ann Partridge, MD, MPH Associate Professor, Department of Medicine, Harvard Medical School Dana-Farber Cancer Institute Boston, MA
Terry Mamounas, MD Medical Director Comprehensive Breast Program MD Anderson Cancer Center Orlando Orlando, FL
NOTE: This activity was presented live on February 2, 2013. If you received CME credit for attending the live activity or participating in the live webcast, you are not eligible to receive credit for this online release. This symposium concentrated on key results presented at the December 2012 San Antonio Breast Cancer Symposium that have the potential to change standards of practice in breast oncology. The multidisciplinary symposium faculty presented data that will inform practice behavior and improve treatment selection and patient care. Panel discussions (informed by audience interaction with the faculty) complemented the lectures. This activity will help participants understand how the new findings should best be applied to current breast cancer diagnosis and treatment strategies. Target Audience
This educational activity is directed toward medical, surgical, and radiation oncologists, pathologists, basic scientists, and others interested in the diagnosis and treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to participate.
Upon completion of this educational activity, the participant should be able to:
Discuss emerging data on and recent advances in the treatment of patients with breast cancer and integrate key findings into clinical practice.
In compliance with ACCME guidelines, Imedex is providing a list of the individuals in a position to control/influence the content of this CME activity and their relevant financial relationships with commercial interests (or absence thereof). Imedex has used a multi-step process to resolve all COI.
Dr. Osipo indicates no relevant financial relationship.
Dr. Gonzalez-Angulo indicates a consultant relationship with Bayer, Celgene, Genentech, and Novartis.
Dr. Albain indicates a financial relationship with Eisai, Genentech/Roche, Genomic Health, Novartis, and Pfizer.
Dr. Korde indicates a financial relationship with Genomic Health.
Dr. Krop indicates a financial relationship with Genentech.
Dr. Partridge indicates no relevant financial relationship.
Dr. Mamounas indicates a speaker/consultant relationship with Celgene, Genentech, and Genomic Health.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Imedex, MCM Education, and Loyola University Chicago.
Imedex is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex designates this enduring material for a maximum of 4.75 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credits TM from organizations accredited by the ACCME. Commercial Support Statements
This activity is supported by educational grants from Genentech, Genomic Health, and AstraZeneca.
This CME activity may discuss the investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for all products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patientís medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Imedex, MCM Education, or any of the companies that provided commercial support for this CME activity.